Out Now: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
Following its recent announcement, the AmoyDx® FGFR1-4 NGS Panel (RUO) is now available offering a robust NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in FGFR1-4 genes at DNA and RNA levels, respectively. The panel covers the full coding sequences of all four genes and utilizes a hybrid capture technology (ddCAP) for library preparation. Its optimized DNA/cDNA co-library preparation workflow mostly takes place within a single reaction tube, enhancing efficiency and ease of use.
Learn more here.
For further information, please contact us at molpath@zytomed-systems.de
Further topics
Qualitative detection of NTRK3 and NTRK1 break apart
Recently, a second ZytoDot ® 2C probe for detecting rearrangements of the NTRK genes has become available: the new ZytoDot ® 2C SPEC NTRK3 Break Apart Probe (C-3079-100). Together with the already existing ZytoDot ® 2C SPEC NTRK1 Break Apart Probe (C-3078-100), a large range of NTRK rearrangements can be covered now. Both probes are designed for the qualitative detection of NTRK3 and NTRK1 rearrangements in FFPE tissue using the ZytoDot ® 2C CISH implementation Kit.
PRAME (EPR20330) in dermatopathology
PRAME (PReferentially-expressed Antigen in MElanoma) was first described in a paper by Ikeda et al., through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. [1, 2]
